Jing Lu1,2, Chi Zhang1, Xi Yang3,4, Xi-Juan Yao1, Qun Zhang2, Xin-Chen Sun1. 1. Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 2. Department of Health Promotion Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 3. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. 4. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Abstract
OBJECTIVE: Hypoxia is prevalent in tumors and plays a pivotal role in resistance to chemoradiotherapy. 18F-MISO (18F-labeled fluoromisonidazole) is currently the preferred choice of PET hypoxia tracers in clinical practice, but has severe disadvantages involving complex labeling methods and low efficient imaging due to lipophilicity. We aimed to design a novel nitroimidazole derivative labeled by 18F via a chelation technique to detect hypoxic regions and provide a basis for planning radiotherapy. MATERIALS AND METHODS: First, we synthesized a 2-nitroimidazole precursor, 2-[4-(carboxymethyl)-7-[2-(2-(2-nitro-1H-imidazol-1-yl)acetamido)ethyl]-1,4,7-triazanonan-1-yl]acetic acid (NOTA-NI). For 18F-labeling, a 18F solution was reacted with a mixture of AlCl3 and NOTA-NI at pH 3.5 and 100°C for 20 min, and the radiochemical purity and stability were evaluated. Biological behaviors of Al18F-NOTA-NI were analyzed by an uptake study in ECA109 normoxic and hypoxic cells, and a biodistribution study and microPET imaging in ECA109 xenografted mice. RESULTS: Al18F-NOTA-NI required a straightforward and efficient labeling procedure compared with 18F-MISO. The uptake values were distinctly higher in hypoxic tumor cells. Animal studies revealed that the imaging agent was principally excreted via the kidneys. Due to hydrophilicity, the radioactivities in blood and muscle were decreased, and we could clearly distinguish xenografted tumors from para-carcinoma tissue by PET imaging. CONCLUSIONS: The nitroimidazole tracer Al18F-NOTA-NI steadily accumulated in hypoxic areas in tumors and was rapidly eliminated from normal tissue. It appears to be a promising candidate for hypoxia imaging with high sensitivity and resolution.
OBJECTIVE: Hypoxia is prevalent in tumors and plays a pivotal role in resistance to chemoradiotherapy. 18F-MISO (18F-labeled fluoromisonidazole) is currently the preferred choice of PET hypoxia tracers in clinical practice, but has severe disadvantages involving complex labeling methods and low efficient imaging due to lipophilicity. We aimed to design a novel nitroimidazole derivative labeled by 18F via a chelation technique to detect hypoxic regions and provide a basis for planning radiotherapy. MATERIALS AND METHODS: First, we synthesized a 2-nitroimidazole precursor, 2-[4-(carboxymethyl)-7-[2-(2-(2-nitro-1H-imidazol-1-yl)acetamido)ethyl]-1,4,7-triazanonan-1-yl]acetic acid (NOTA-NI). For 18F-labeling, a 18F solution was reacted with a mixture of AlCl3 and NOTA-NI at pH 3.5 and 100°C for 20 min, and the radiochemical purity and stability were evaluated. Biological behaviors of Al18F-NOTA-NI were analyzed by an uptake study in ECA109 normoxic and hypoxic cells, and a biodistribution study and microPET imaging in ECA109 xenografted mice. RESULTS: Al18F-NOTA-NI required a straightforward and efficient labeling procedure compared with 18F-MISO. The uptake values were distinctly higher in hypoxic tumor cells. Animal studies revealed that the imaging agent was principally excreted via the kidneys. Due to hydrophilicity, the radioactivities in blood and muscle were decreased, and we could clearly distinguish xenografted tumors from para-carcinoma tissue by PET imaging. CONCLUSIONS: The nitroimidazole tracer Al18F-NOTA-NI steadily accumulated in hypoxic areas in tumors and was rapidly eliminated from normal tissue. It appears to be a promising candidate for hypoxia imaging with high sensitivity and resolution.
Authors: Sven De Bruycker; Christel Vangestel; Tim Van den Wyngaert; Patrick Pauwels; Leonie Wyffels; Steven Staelens; Sigrid Stroobants Journal: J Nucl Med Date: 2018-07-06 Impact factor: 10.057
Authors: Gaber Komar; Marko Seppänen; Olli Eskola; Paula Lindholm; Tove J Grönroos; Sarita Forsback; Hannu Sipilä; Sydney M Evans; Olof Solin; Heikki Minn Journal: J Nucl Med Date: 2008-11-07 Impact factor: 10.057
Authors: William J McBride; Robert M Sharkey; Habibe Karacay; Christopher A D'Souza; Edmund A Rossi; Peter Laverman; Chien-Hsing Chang; Otto C Boerman; David M Goldenberg Journal: J Nucl Med Date: 2009-05-14 Impact factor: 10.057
Authors: Ernst J Postema; Alexander J B McEwan; Terence A Riauka; Piyush Kumar; Dacia A Richmond; Douglas N Abrams; Leonard I Wiebe Journal: Eur J Nucl Med Mol Imaging Date: 2009-05-09 Impact factor: 9.236
Authors: T Kurokawa; M Miyamoto; K Kato; Y Cho; Y Kawarada; Y Hida; T Shinohara; T Itoh; S Okushiba; S Kondo; H Katoh Journal: Br J Cancer Date: 2003-09-15 Impact factor: 7.640